Please login to the form below

Not currently logged in
Email:
Password:

Vizamyl

This page shows the latest Vizamyl news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • Biosimilar Lantus leads CHMP opinions Biosimilar Lantus leads CHMP opinions

    event. In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease. ... Vizamyl is a biomarker that can detect amyloid-beta neuritic plaques, where are formations in the brain associated with

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    18F) and GE Healthcare's Vizamyl (flutemetamol F18) on the market.

  • FDA approves Alzheimer's diagnostic drug FDA approves Alzheimer's diagnostic drug

    FDA approves Alzheimer's diagnostic drug. GE Healthcare's Vizamyl to compete with Lilly's Amyvid. ... A PET scan can then detect the presence of Vizamyl, allowing physicians to evaluate for the presence of beta amyloid.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics